Challenges predicting ligand-receptor interactions of promiscuous proteins: The nuclear receptor PXR

PLoS Computational Biology

Volumn 5, Issue 12, 2009, Pages

  Ekins, Sean ^a,b,c   Kortagere, Sandhya ^d   Iyer, Manisha ^e   Reschly, Erica J ^e   Lill, Markus A ^f   Redinbo, Matthew R ^g,h,i   Krasowski, Matthew D ^e,j  

^a Collaborations in Chemistry ^*  (United States)

^b Department of Pharmaceutical Sciences ^*  (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f PURDUE UNIVERSITY   (United States)

^g University of North Carolina at Chapel Hill   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BAYESIAN NETWORKS; CELL DEATH; COMPUTATIONAL CHEMISTRY; DETOXIFICATION; FORECASTING; LEARNING SYSTEMS; LIPIDS; STEROID HORMONES; TOXICITY;

ADVERSE EFFECT; BASED MODELLING; COMPUTATIONAL PREDICTIONS; LIGAND-RECEPTOR INTERACTIONS; MODELING APPROACH; NUCLEAR RECEPTORS; PHARMACEUTICAL RESEARCH; PHYSIOLOGICAL PROCESS; TOXICOLOGICAL RESEARCH; TRANSCRIPTIONAL REGULATION;

LIGANDS;

HYPERFORIN; PREGNANE X RECEPTOR; STEROID; LIGAND; STEROID RECEPTOR;

ARTICLE; BAYES THEOREM; CHEMICAL MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; FIVE DIMENSIONAL IMAGING; FOUR DIMENSIONAL IMAGING; IMAGING AND DISPLAY; LIGAND BINDING; PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING; TWO DIMENSIONAL IMAGING; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; DRUG POTENTIATION; HUMAN; METABOLISM; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN STRUCTURE, TERTIARY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, STEROID;

EID: 74549144266     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1000594     Document Type: Article

References (57)

1. Ekins S (2004) Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discovery Today 9: 276-285.
2. Krasowski MD, Reschly EJ, Ekins S (2008) Intrinsic disorder in nuclear hormone receptors. J Proteome Res 7: 4359-4372.
3. Dunker AK, Brown CJ, Lawson JD, Iakoucheva LM, Obradovic Z (2002) Intrinsic disorder and protein function. Biochemistry 41: 6573-6582.
4. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, et al. (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 95: 12208-12213.
5. Blumberg B, Sabbagh W Jr, Juguilon H, Bolado J, Jr., van Meter CM, et al. (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12: 3195-3205.
6. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, et al. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signalling pathway. Cell 92: 73-82.
7. Verma S, Tabb MM, Blumberg B (2009) Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells. BMC Cancer 9: 3.
8. Gupta D, Venkatesh M, Wang H, Kim S, Sinz M, et al. (2008) Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer. Clin Cancer Res 14: 5332-5340.
9. Zhou J, Liu M, Zhai Y, Xie W (2008) The antiapoptotic role of pregnane X receptor in human colon cancer cells. Mol Endocrinol 22: 868-880.
10. Biswas A, Mani S, Redinbo MR, Krasowski MD, Li H, et al. (2009) Elucidating the 'Jekyll and Hyde' nature of PXR: The case for discovering antagonists. Pharm Res 26: 1807-1815.
11. Urquhart BL, Tirona RG, Kim RB (2007) Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 47: 566-578.
12. Mani S, Redinbo MR, Krasowski MD, Biswas A, Li H, et al. (2009) Elucidating the 'Jekyll and Hyde' Nature of PXR: The Case for Discovering Antagonists Pharm Res Submitted.
13. Khandelwal A, Krasowski MD, Reschly EJ, Sinz MW, Swaan PW, et al. (2008) Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol 21: 1457-1467.
14. Watkins RE, Davis-Searles PR, Lambert MH, Redinbo MR (2003) Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J Mol Biol 331: 815-828.
15. Watkins RE, Maglich JM, Moore LB, Wisely GB, Noble SM, et al. (2003) 2.1A crystal structure of human PXR in complex with the St John's Wort compound hyperforin. Biochemistry 42: 1430-1438.
16. Xue Y, Chao E, Zuercher WJ, Willson TM, Collins JL, et al. (2007) Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. Bioorg Med Chem 15: 2156-2166.
17. Chrencik JE, Orans J, Moore LB, Xue Y, Peng L, et al. (2005) Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol Endocrinol 19: 1125-1134.
18. Teotico DG, Bischof JJ, Peng L, Kliewer SA, Redinbo MR (2008) Structural basis of human pregnane X receptor activation by the hops constituent colupulone. Mol Pharmacol 74: 1512-1520.
19. Xue Y, Moore LB, Orans J, Peng L, Bencharit S, et al. (2007) Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol 21: 1028-1038.
20. Ghose AK, Viswanadhan VN, Wendoloski JJ (1998) Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: an analysis of ALOGP and CLOGP methods. J Phys Chem 102: 3762-3772.
21. Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, et al. (2001) The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292: 2329-2333.
22. Kortagere S, Chekmarev D, Welsh WJ, Ekins S (2008) Hybrid scoring and classification approaches to predict human pregane X receptor activiators. Pharm Res In press.
23. Ekins S, Mirny L, Schuetz EG (2002) A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRa and LXRb. Pharm Res 19: 1788-1800.
24. Jacobs MN (2004) In silico tools to aid risk assessment of endocrine disrupting chemicals. Toxicology 205: 43-53.
25. Ekins S, Andreyev S, Ryabov A, Kirillov E, Rakhmatulin EA, et al. (2006) A Combined Approach to Drug Metabolism and Toxicity Assessment. Drug Metab Dispos 34: 495-503.
26. Bachmann K, Patel H, Batayneh Z, Slama J, White D, et al. (2004) PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol Res 50: 237-246.
27. Ekins S, Chang C, Mani S, Krasowski MD, Reschly EJ, et al. (2007) Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol 72: 592-603.
28. Ekins S, Erickson JA (2002) A pharmacophore for human pregnane-X-receptor ligands. Drug Metab Dispos 30: 96-99.
29. Schuster D, Langer T (2005) The identification of ligand features essential for PXR activation by pharmacophore modeling. J Chem Inf Model 45: 431-439.
30. Ung CY, Li H, Yap CW, Chen YZ (2007) In silico prediction of pregnane X receptor activators by machine learning approaches. Mol Pharmacol 71: 158-168.
31. Ekins S, Reschly EJ, Hagey LR, Krasowski MD (2008) Evolution of pharmacologic specificity in the pregnane X receptor. BMC Evol Biol 8: 103.
32. Cramer RD, Patterson DE, Bunce JD (1988) Comparative Molecular Field Analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110: 5959-5967.
33. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, et al. (2003) Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res 20: 1794-1803.
34. Azzaoui K, Hamon J, Faller B, Whitebread S, Jacoby E, et al. (2007) Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMed-Chem 2: 874-880.
35. Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J, et al. (2008) A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos 36: 1689-1697.
36. Mnif W, Pascussi JM, Pillion A, Escande A, Bartegi A, et al. (2007) Estrogens and antiestrogens activate PXR. Toxicol Lett 170: 19-29.
37. Hassan M, Brown RD, Varma-O'brien S, Rogers D (2006) Cheminformatics analysis and learning in a data pipelining environment. Mol Divers 10: 283-299.
38. Gao YD, Olson SH, Balkovec JM, Zhu Y, Royo I, et al. (2007) Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach. Xenobiotica 37: 124-138.
39. DeLano WL (2002) The PyMOL Molecular Graphics System.
40. Lill MA, Vedani A, Dobler M (2004) Raptor: combining dual-shell representation, induced-fit simulation, and hydrophobicity scoring in receptor modeling: application toward the simulation of structurally diverse ligand sets. J Med Chem 47: 6174-6186.
41. Teotico DG, Frazier ML, Ding F, Dokholyan NV, Temple BR, et al. (2008) Active nuclear receptors exhibit highly correlated AF-2 domain motions. PLoS Comput Biol 4: e1000111.
42. Rogers D, Brown RD, Hahn M (2005) Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening followup. J Biomol Screen 10: 682-686.
43. Prathipati P, Ma NL, Keller TH (2008) Global Bayesian models for the prioritization of antitubercular agents. J Chem Inf Model 48: 2362-2370.
44. Metz JT, Huth JR, Hajduk PJ (2007) Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups. J Comput Aided Mol Des 21: 139-144.
45. Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, et al. (2007) Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off-Target Effects from Chemical Structure. ChemMedChem 2: 861-873.
46. Nidhi, Glick M, Davies JW, Jenkins JL (2006) Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J Chem Inf Model 46: 1124-1133.
47. Kortagere S, Chekmarev D, Welsh WJ, Ekins S (2009) Hybrid scoring and classification approaches to predict human pregane X receptor activiators. Pharm Res 26: 1001-1011.
48. Tetko IV, Bruneau P, Mewes HW, Rohrer DC, Poda GI (2006) Can we estimate the accuracy of ADME-Tox predictions? Drug Discov Today 11: 700-707.
49. Tetko IV, Sushko I, Pandey AK, Zhu H, Tropsha A, et al. (2008) Critical assessment of QSAR models of environmental toxicity against Tetrahymena pyriformis: focusing on applicability domain and overfitting by variable selection. J Chem Inf Model 48: 1733-1746.
50. Suarez M, Tortosa P, Carrera J, Jaramillo A (2008) Pareto optimization in computational protein design with multiple objectives. J Comput Chem 29: 2704-2711.
51. Lill MA, Dobler M, Vedani A (2006) Prediction of Small-Molecule Binding to Cytochrome P450 3A4: Flexible Docking Combined with Multidimensional QSAR. ChemMedChem 6: 73-81.
52. Feng J, Sanil A, Young SS (2006) PharmID: pharmacophore identification using Gibbs sampling. J Chem Inf Model 46: 1352-1359.
53. Kortagere S, Krasowski MD, Ekins S (2009) The importance of discerning shape in molecular pharmacology. Trends Pharmacol Sci 30: 138-147.
54. Krasowski MD, Yasuda K, Hagey LR, Schuetz EG (2005) Evolution of the pregnane x receptor: adaptation to cross-species differences in biliary bile salts. Mol Endocrinol 19: 1720-1739.
55. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267: 727-748.
56. Klon AE, Lowrie JF, Diller DJ (2006) Improved naive Bayesian modeling of numerical data for absorption, distribution, metabolism and excretion (ADME) property prediction. J Chem Inf Model 46: 1945-1956.
57. Lill MA, Vedani A (2006) Combining 4D pharmacophore generation and multidimensional QSAR: Modeling ligand binding to the Bradykinin B2 receptor. J Chem Inf Model 46: 2135-2145.